In turn, as highlighted by numerous studies in CLL (245–248) and other hematological malignancies (249, 250), activated ECs critically contribute to malignant B cell survival through factors such as B-cell activating factor (BAFF) (245, 251, 252) (Figure 2A). This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.